Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

There are many opportunities available in the international markets that never make the news in the US. The VEA and VWO ETFs ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...